Brian Druker, M.D.
The Knight Cancer Institute at Oregon Health & Science University
With LLS support, Dr. Druker pioneered targeted therapy, a cornerstone of precision medicine. His work led to the development of imatinib (Gleevec®), which revolutionized CML treatment and has saved 350,000 lives globally. Today, Dr. Druker is driving innovation in precision medicine through our Beat AML Master Clinical Trial.